April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Retinal-choroidal changes after intravitreal ranibizumab in diabetic macular edema:12 months follow-up
Author Affiliations & Notes
  • Paola Giorno
    Retina, Fondazione GB Bietti-IRCCS, Roma, Italy
  • Mariacristina Parravano
    Retina, Fondazione GB Bietti-IRCCS, Roma, Italy
  • Francesco Oddone
    Retina, Fondazione GB Bietti-IRCCS, Roma, Italy
  • Andrea Cacciamani
    Retina, Fondazione GB Bietti-IRCCS, Roma, Italy
  • Fabio Scarinci
    Retina, Fondazione GB Bietti-IRCCS, Roma, Italy
  • Antonluca Boninfante
    Retina, Fondazione GB Bietti-IRCCS, Roma, Italy
  • Monica Varano
    Retina, Fondazione GB Bietti-IRCCS, Roma, Italy
  • Footnotes
    Commercial Relationships Paola Giorno, None; Mariacristina Parravano, Allergan (S), Bayer (S), Novartis (S); Francesco Oddone, None; Andrea Cacciamani, None; Fabio Scarinci, None; Antonluca Boninfante, None; Monica Varano, Allergan (S), Bayer (S), Novartis (S)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 576. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paola Giorno, Mariacristina Parravano, Francesco Oddone, Andrea Cacciamani, Fabio Scarinci, Antonluca Boninfante, Monica Varano; Retinal-choroidal changes after intravitreal ranibizumab in diabetic macular edema:12 months follow-up. Invest. Ophthalmol. Vis. Sci. 2014;55(13):576.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: to explore long term retinal and choroidal changes, using enhanced depth imaging optical coherence tomography (EDI-OCT), and visual function changes after intravitreal ranibizumab 0.5 mg in patients with diabetic macular edema (DME)

Methods: Consecutive patients with a diagnosis of DME were enrolled in this prospective, noncomparative case series and treated with repeated intravitreal injections of ranibizumab 0.5 mg. At baseline patients performed a complete eye examination including BCVA with ETDRS charts, slit lamp examination, IOP measurement, ophthalmoscopy, retinal and choroidal thickness measurement using enhanced depth imaging optical coherence tomography (EDI-OCT, Spectralis; Heidelberg Engineering GmbH, Heidelberg, Germany). All patients were treated with 3 injections of ranibizumab 0.5 mg 1 month apart till VA stabilization and retreated according to predefined criteria, based on VA and OCT, evaluated monthly for a period of up to 12 months.

Results: 23 DMO eyes of 23 patients with diabetes (14 male; 9 female, type 1: 4/23 and type 2: 19/23) with a mean age of 66.2±8.3 years were included in this analysis. Mean diabetes duration was 16.13±8.5 years. After ranibizumab 0.5 mg loading phase mean BCVA significantly improved from 0.5±1.5 to 0.4±1.4 logMar (p<.0001) and to 0.3±1.5 logMar (p<.0001) after 12 months of follow up. OCT central retinal thickness (CRT) significantly reduced from 583.4±141.5 to 434.4±136.3 μm (p<.0001), and to 427.3±167.7 μm (p<.0001) after 12 months follow-up. Choroidal thickness (CT), measured either manual and automatic (R2 0.9, p<.0001), showed a slight, not significant increase from 189.3±49.9 to 209.6±60.6 after the loading phase and to 191.3± 60.3 μm after 12 months follow-up (p>0.5). Not significant relationship was found between either changes in CRT and BCVA (R2 0.11, p=0.1) and changes in CT and BCVA (R2 0.05, p=0.28). No significant relationship was found between CRT and CT (R2 0.0006, p=0.7).

Conclusions: Intravitreal injection of ranibizumab in DME eyes causes slight, not significant changes of choroidal thickness associated with an improvement of visual acuity and a reduction of retinal thickness at 12 months of follow up.

Keywords: 499 diabetic retinopathy • 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • 452 choroid  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×